Many patients require intensive insulin therapy to achieve optimal control, putting these patients at high risk for hypoglycemia and severe hypoglycemia.16,††
Medicare coverage is available for the FreeStyle Libre 2 system if the FreeStyle Libre 2 reader is used to review glucose data on some days every month. Medicare and other third party payor criteria apply. Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
The FreeStyle Libre 2 system is indicated for use in people with diabetes age 4 and older.
* The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.
† The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
‡ Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device. You must have Critical Alerts enabled to receive alarms and alerts on your smartphone.
§ The user's device must have internet connectivity for glucose data to automatically upload to LibreView.
|| The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
¶ The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
# The FreeStyle Libre 2 system shares the same features as previous versions of the FreeStyle Libre system with the addition of optional real-time alarms. Therefore, it is expected that the FreeStyle Libre 2 system should have similar benefits and the data are applicable.
** Includes ambulance visits, ED visits, and hospitalizations (29.3% rate of ambulance attendance per severe hypoglycemic event13; $214.47 per ambulance attendance, updated to $232 per medical care CPI14; 17% rate of ED visit per severe hypoglycemic event15; $1,387 per ED visit and $17,564 per hospitalization, updated to $1,645 and $20,840 per medical care CPI, respectively.11)
†† Severe hypoglycemic events are defined by events requiring external third-party assistance, or leading to coma or convulsion. ǂǂ Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§§ Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
|||| Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life.
References: 1. FreeStyle Libre 2 AMCP Dossier 2. Charleer S, et al. Diabetes Care. 2020;43(2):389-397. https://doi.org/10.2337/dc19-1610 3. Fokkert, M. BMJ Open Diabetes Research & Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 4. Bergenstal, R. Journal of the Endocrine Society (2021): https://doi.org/10.1210/jendso/bvab013 5. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 6. Haak, T. Diabetes Therapy (2017): https://doi.org/10.1007/s13300-016-0223-6 7. Miller, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 8. Kerr, Matthew SD, et al. “CGM Use Associated With Reduction in Acute Diabetes Complications, Even in Patients Using Less Than Four Test Strips Per Day.” Poster presented at the ATTD Advanced Technologies & Treatments for Diabetes Conference, Madrid, Spain, February 19-22, 2020. https://doi.org/10.1089/dia.2020.2525.abstracts 9. Deshmukh, H. Diabetes Care (2020): 2153-2160. https://doi.org/10.2337/dc20-0738 10. ADA. Diabetes Care (2018): https://doi.org/10.2337/dci18-0007 11. DCCT Research Group. N Engl J Med. 1993;329(14):977-986. https://doi.org/10.1056/NEJM199309303291401 12. Heller, SR. Diabetic Medicine (2015): https://doi.org/10.1111/dme.12844 13. Foos, V. J Med Econ (2015): https://doi.org/10.3111/13696998.2015.1006730 14. Bullano, MF. Am J Health Syst Pharm (2006): https://doi.org/10.2146/ajhp050552 15. Quilliam, BJ. Am J Manag Care (2011): https://doi.org/10.1016/j.clinthera.2011.09.020 16. “Epidemiology of Severe Hypoglycemia in the Diabetes Control and Complications Trial.” Am J Med. 1991,90(1): 450-59. 90, no. 1 (1991): 450–59. https://doi.org/10.1016/0002-9343(91)90605-w 17. Campbell, F. Pediatric Diabetes (2018): https://doi.org/10.1111/pedi.12735 18. Tyndall, V. Diabetologia 62 (2019): https://doi.org/10.1007/s00125-019-4894-1 19. Evans, M. Diabetes Therapy (2020): https://doi.org/10.1007/s13300-019-00720-0 20. Wright, E. Diabetes Spectrum (2021): https://doi.org/10.2337/ds20-0069 21. Kroger, J. Diabetes Therapy (2020): https://doi.org/10.1007/s13300-019-00741-9 22. Carlson AL, et al. Glucose control after initiation of flash glucose monitoring in type 2 diabetes managed with basal insulin: retrospective real-world chart review study from the US. [64-LB]. Poster presented at: American Diabetes Association 81st Scientific Sessions, Virtual, June 25-29, 2021. https://doi.org/10.2337/db21-64-LB 23. Calliari, L. Diabetology & Metabolic Syndrome (2020): https://doi.org/10.1186/s13098-019-0513-z 24. Ogawa, W. Poster presented at: American Diabetes Association 81st Scientific Session, Virtual, June 25-29, 2021. https://doi.org/10.2337/db21-607-P 25. Dunn, T. Diabetes Research and Clinical Practice (2018): https://doi.org/10.1016/j.diabres.2017.12.015 26. Lang, J. Diabetes (2019): https://doi.org/10.2337/db19-972-p 27. Varughese, B. Diabetes Stoffw Herz 2021;30:231-242. 28. Data on file. Abbott Diabetes Care. 29. Miller E, et al. Diabetes (2021). https://doi.org/10.2337/db21-67-LB
ADC-17128 v7.0 02/22
Payer.freestylelibre.us/en is a product-specific website intended only for residents of the United States.
If you are a resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.
ADC-21099 v3.0 07/21